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Abstract Vasculogenic mimicry (VM) is known as non-
endothelial tumor cell-lined microvascular channels in
aggressive tumors. We have previously found the presence
of VM in high-grade gliomas. In this study, we aimed to
identify VM patterns in gliomas and to explore their clinical
signiﬁcance. Tumor samples as well as their detailed clin-
ical/prognostic data were collected from 101 patients.
Vasculogenic mimicry in the glioma samples was deter-
mined by dual staining for endothelial marker CD34 and
periodic acid–Schiff (PAS). Tumor samples were also
immunohistochemically stained for Ki-67, VEGF, COX-2
and MMP-9. The association between VM and the clinical
characteristics of the patients were analyzed. A Kaplan–
Meier survival analysis and log-rank tests were performed
to compare survival times of the patients. Vasculogenic
mimicry was present in 13 out of 101 samples. The higher
grade gliomas had a higher incidence of VM than that of
lower grade gliomas (P = 0.006). Vasculogenic mimicry
channels were associated with the expression of COX-2 and
MMP-9 (P\0.05). While there was no association
between the existence of VM and the sex, age and preop-
erative epilepsy of the patients, or expression of Ki-67 and
VEGF. However, patients with VM-positive gliomas sur-
vived a shorter period of time than those with VM negative
gliomas (P = 0.027). Interestingly, in high-grade gliomas,
the level of microvascular density was lower in VM positive
tumors than those VM negative tumors (P = 0.039). Our
results suggest that VM channels in gliomas correlate with
increasing malignancy and higher aggressiveness, and may
provide a complementation to the tumor’s blood supply,
especially in less vascularized regions, which may aid in the
identiﬁcation of glioma patients with a poorer prognosis.
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Introduction
Glioma is the most common primary brain tumor,
accounting for about 50% of all central nervous system
neoplasms. The prognosis for glioma patients is not satis-
factory despite multimodality management with surgery,
radiation, and chemotherapy. The median survival time for
patients with glioblastoma multiforme (GBM), the most
malignant glioma, is still only 1 year [1]. Prolonging sur-
vival in glioma patients remains a challenge in the ﬁeld of
neuro-oncology.
In 1999, Maniotis et al. [2] reported that highly
aggressive uveal melanomas could form blood vessels by
tumor cells instead of endothelial cells, and named this
phenomenon of tumor vascularization as vasculogenic
mimicry (VM). Since then, VM has been described in
several malignant tumors including prostatic carcinoma
[3], inﬂammatory and ductal breast carcinoma [4], ovarian
carcinoma [5], rhabdomyosarcoma [6] and osteosarcoma
[7]. Vasculogenic mimicry has also been implicated in
invasion and metastasis, and is associated with poor
prognosis in hepatocellular carcinoma [8] and gastrointes-
tinal stromal tumors [9]. The presence of VM is associated
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There is limited data regarding VM in human gliomas.
We previously reported the presence of VM in human
gliomas [11]. The aim of this study was to perform a
systematic evaluation of VM in gliomas of different grades
and to correlate such ﬁndings with clinicopathological
parameters.
Materials and methods
Patients and tissue samples
One hundred and one patients pathologically diagnosed
with gliomas from 2000 to 2006 at Cancer Center of Sun
Yat-sen University were analyzed. All patients received
craniotomy for tumor resection and had detailed clinical
follow-up data. Tumor sections were reviewed by two
neuropathologists to verify diagnosis according to World
Health Organization (WHO) 2007 classiﬁcation standards
for central nervous system tumors [12]. Only astrocytic
tumors were included in this study. The series consisted of
6 grade I astrocytomas, 35 grade II astrocytomas, 39 grade
III anaplastic astrocytomas (AA), and 21 grade IV glio-
blastoma multiformes (GBM). Patients with mixed gliomas
were excluded from the study.
CD34–PAS dual staining
Vasculogenic mimicry was detected by CD34–PAS dual
staining as described previously [11]. Brieﬂy, standard
immunohistochemical staining was performed on 5-l for-
malin-ﬁxed parafﬁn-embedded tumor sections, for CD34
(1:200, polyclonal antibody; Santa Cruz Biotechnology),
followed by immunodetection using the EnVision
TM ?
System (Peroxidase Kit; Santa Cruz Biotechnology). The
slides were then rinsed with distilled water for 5 min,
incubated with periodic acid–Schiff (PAS) for 15 min,
counterstained with Mayer’s hematoxylin for 1 min, and
viewed under a light microscope to detect CD34 and PAS
signals.Thewhole section was examinedfor the presence of
VM (CD34-negative and PAS-positive vessels) by three
independent observers without knowledge of patient out-
come. Microvascular density (MVD) was evaluated by
counting CD34-positive cells in 10 randomly selected ﬁelds
at high magniﬁcation and the average counts were then
calculated. Adult liver samples were used as controls.
Immunohistochemical studies
Formalin-ﬁxed parafﬁn-embedded specimens were ana-
lyzed by immunohistochemistry with antibodies of glial
ﬁbrillary acidic protein (GFAP) (1:500; Dakocytomation,
Glostrup, Denmark), Ki-67, VEGF, COX-2 and MMP-9
(1:200; Santa Cruz Biotechnology) according to manufac-
tory instruction. Immunodetection was performed using the
EnVision
TM ? System (Peroxidase Kit; Santa Cruz Bio-
technology). The slides were rinsed with distilled water for
5 min, counterstained with Mayer’s hematoxylin for 1 min,
dehydrated through an alcohol gradient and cover-slipped.
Tissues from ﬁve normal brains (from decompression
surgery for head injury patients) served as controls.
Nuclear staining for Ki-67 and cytoplasmic staining for
VEGF, COX-2 and MMP-9 were considered positive. The
degree of immunostaining was scored separately by two
independent investigators, who were blinded to the histo-
pathologic features. The scoring of Ki-67 was based on
percent positivity [13]. Tumors were classiﬁed as 0 for
negative, 1 for B10%, 2 for 10–25% and 3 for C25%
staining. The intensity of staining was graded as 0 for
absent immunoreactivity, 1 for weak, 2 for moderate, and 3
for intense positivity. The staining intensity index of
VEGF, COX-2 and MMP-9 was determined by multiplying
the proportion of positively stained tumor cells and the
intensity of staining.
Statistical analysis
The statistical analysis was performed with SPSS v.13.0 for
Windows. Associations between VM and clinical data were
determined by the Pearson’s v
2 test. A Kaplan–Meier sur-
vival analysis and log-ranktests were performed to compare
survival times of patients between the VM and non-VM
groups. The multivariate survival analysis was calculated
according to the Cox proportional hazards model. The
threshold for statistical signiﬁcance was P = 0.05.
Results
Clinical data of the patients
Table 1summarizestheclinicopathologicalcharacteristicsof
the101gliomacasesstudied.Therewere64(63.4%)maleand
37(36.6%)femalepatientsandthemedianageofpatientswas
35 years old (range 2–69 years old). The majority of patients
(70.3%) had preoperative Karnofsky performance scores
(KPS) of 70 or greater. The median follow-up period was
20 months (range from 1 to 75 months).
Vasculogenic mimicry is correlated with tumor grade
Although a PAS-positive pattern was seen in most of the
samples, CD34-negative and PAS-positive channels, which
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(12.9%) examined (Fig. 1). The cells composing the chan-
nels were negative for CD34 indicating that they were not
endothelial or endothelial progenitor cells. The detection of
GFAP expression in cells around the VM channels con-
ﬁrmed the cells as astrocytic tumor cells (Fig. 1).
To determine the clinical signiﬁcance of VM in glio-
mas, we compared the presence of VM with clinico-
pathological characteristics of the patients. Vasculogenic
mimicry was detected preferentially in high-grade glio-
mas: 8 of 21 WHO grade IV (38.1%), 3 of 39 WHO
grade III (7.7%), and 2 of 35 WHO grade II (5.7%). In
contrast, no VM was found in any WHO grade I gliomas
examined. The high-grade (WHO grades III and IV)
gliomas had a higher incidence of VM than that of low-
grade (WHO grades I and II) gliomas (P = 0.006)
(Table 1). No associations were found between the exis-
tence of VM and the sex, age, preoperative KPS, pre-
operative epilepsy of the patients, and extent of tumor
resection (Table 1).
Vasculogenic mimicry is associated with COX-2
and MMP-9 expressions
No signiﬁcant associations were found between VM and
Ki-67 labeling index or VEGF staining intensity index
(Table 2). Tumor specimens that expressed high levels of
COX-2 proteins had VM, whereas tumors (generally low-
grade gliomas) with low or no COX-2 expression had
fewer evidence of VM (P\0.05) (Table 2). Signiﬁcant
association was found between the existence of VM and
MMP-9 expression (P\0.05) (Table 2).
Vasculogenic mimicry is a predictor of poor prognosis
Using the Kaplan–Meier survival analysis, we compared
the survival times between patients with and without VM
tumors. In patients with VM-positive gliomas, the median
survival time was 15 months (95% CI, 2–28 months),
compared with a median survival time of 38 months (95%
CI, 25–50 months) for patients with VM-negative tumors
Table 1 Clinical data and VM in glioma patients
n VM positive VM negative v
2 P value
Sex
Female 37 3 34 0.606 0.436
a
Male 64 10 54
Age (years)
\40 63 7 56 2.872 0.220
b
C40 to[50 10 0 10
C50 28 6 22
Karnofsky performance scale
C70 71 8 63 0.172 0.678
a
\70 30 5 25
Preoperative epilepsy
Yes 25 2 23 0.244 0.621
a
No 76 11 65
High intra-cranial pressure
Yes 60 9 51 0.597 0.440
a
No 41 4 37
Tumor grade
WHO I 6 0 6 11.442 0.006
b
WHO II 35 2 33
WHO III 39 3 36
WHO IV 21 8 13
Extent of tumor resection
Gross-total/subtotal resection 82 11 71 0.363 0.547
a
Partial resection 29 2 27
a Pearson v
2 test (asymptotic signiﬁcance, two-sided)
b Fisher’s exact test (two-sided)
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123(P = 0.027) (Fig. 2). Since survival in patients with brain
tumors has been associated with several clinicopathologi-
cal variables, we attempted to deﬁne the relative contri-
bution of VM expression to survival. Expression of VM
correlated signiﬁcantly with postoperative survival by
univariate analysis (P = 0.028). The age, KPS, and tumor
histology also correlated with survival by univariate anal-
ysis. Multivariate analysis and cox proportional hazards
model indicated that age and tumor grade were indepen-
dent predictors of poor prognosis (P = 0.003 and P =
0.004, respectively) for glioma patients.
Vasculogenic mimicry is associated with lower
MVD in high-grade gliomas
The levels of MVD in low-grade (WHO grades I and II) and
high-grade (WHO III and IV) gliomas were 21.41 ± 18.38
and 34.10 ± 32.52, respectively. However, no signiﬁcant
correlation was found between MVD and postoperative
survival by univariate analysis (P = 0.110). We then
explored potential association between VM and MVD in
high-grade gliomas. Microvascular density was detected at
a higher level in VM-negative tumors (45.17 ± 38.96) than
in VM-positive tumors (21.67 ± 20.05) in high-grade gli-
omas (Z =- 2.064, P = 0.039) (Table 3).
Discussion
For years, sprouting angiogenesis has been considered an
exclusive mechanism of tumor vascularization. However,
Fig. 1 Representative
micrographs of VM in glioma.
a PAS-positive (purple-red)
zone without CD34 positive
cells indicate VM; some
angiogenesis vessels are seen
with CD34 stained (brown) cells
in the internal lumen of vessels.
b A magniﬁcation of image (a);
erythrocyte shadows are seen in
the channels. c The cells
composing the channels were
negative for CD34 indicating
that they were not endothelial or
endothelial progenitor cells
(VM zone); and CD34-positive
and PAS-positive channels are
seen in the same view
(endothelial vessels). d Cells
around the channels are stained
positive for GFAP indicating
that they are astrocytic tumor
cells. Scale bars 50 lm. (Color
ﬁgure online)
Table 2 Correlation of VM with Ki-67, VEGF, COX-2 and MMP-9
in gliomas
VM positive VM negative ZP value
Ki-67 1.54 ± 1.20 1.13 ± 0.71 -1.242 0.214
VEGF 75.47 ± 74.47 47.50 ± 60.13 -1.474 0.141
COX-2 87.31 ± 63.20 43.92 ± 45.92 -2.645 0.008*
MMP-9 94.62 ± 82.09 41.93 ± 60.79 -2.896 0.004*
* P\0.05
Fig. 2 Patients whose tumors have VM show shorter survival than
those without VM (P = 0.027) by Kaplan–Meier survival analysis
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123over the last decade, several other tumor vascularization
mechanisms have been identiﬁed, including vessel-coop-
tion, intussusception and recruitment of endothelial pre-
cursor cells. One mechanism that does not involve
endothelial cells, namely VM, has also been reported. The
latter describes a mechanism by which highly aggressive
tumor cells form vessel-like structures themselves, by
virtue of their high plasticity. According to Maniotis et al.
[2], VM channels are patterned networks of interconnected
loops of PAS-positive extracellular matrix that may be
solid or hollow, with no involvement of endothelial cells
but with red blood cells readily detectable inside such
channels. The current study investigated the prevalence and
clinical signiﬁcance of VM in gliomas. CD34-negative and
PAS-positive channels were detected in 12.9% of astro-
cytic tumors examined. The VM channels were arranged in
arcs, loops and networks. These results were in line with
our previous ﬁndings of VM in gliomas [11]. Vasculogenic
mimicry was detected predominantly in high-grade glio-
mas and a signiﬁcant association was found between VM
and tumor grade.
The VEGF stimulates proliferation of endothelial cells
through speciﬁc tyrosine kinase receptors,ﬂt-1 andﬂt/KDR,
and is a central regulator of the angiogenic process [14, 15].
We performed immunostaining for Ki-67 and VEGF to
further evaluate whether VM channels in gliomas were
associatedwithcellproliferation.Inthisstudy,nosigniﬁcant
associationshavebeenfoundbetweenVMandexpressionof
Ki-67 or VEGF. These results indicate that VM in gliomas
may be distinct from endothelial lined vessels.
The COX-2, inducible isoform of prostaglandin H syn-
thase, has been implicated in the growth and progression of
a variety of human cancers. Over-expression of COX-2 is
known to correlate with the aggressive and invasive
potential of tumor cells [16]. It has been reported that
breast tumor cells over-expressing COX-2 developed vas-
cular channels when plated on three-dimensional matrigel
cultures [17, 18]. We hypothesized that COX-2 may play a
role in VM formation. To this end, we evaluated COX-2
expression in gliomas by immunohistochemistry and cor-
related the results with VM. A signiﬁcant association was
observed between VM and COX-2 expression, suggesting
that COX-2 could contribute to VM formation.
Matrix metalloproteinases (MMPs) are enzymes that
promote tumor invasion and angiogenesis by enzymatically
remodeling the extracellular matrix. MMP-9 is the most
abundant form of MMPs in malignant gliomas. Our result
revealed a signiﬁcant association between VM and MMP-9
expression. These results provide evidence that VM may
associatewiththeaggressiveandinvasivenatureofgliomas.
Vasculogenic mimicry channels have been observed in
several tumor types and the occurrence is strongly associ-
ated with a poor prognosis. Guzman et al. [8] reported that
VM of the patterned matrix type was present in hepato-
cellular carcinoma and was associated with tumor recur-
rence after orthotopic liver transplantation. Vasculogenic
mimicry is also involved in the invasion and metastasis of
malignant tumors and has been associated with poor
prognosis in malignant esophageal stromal tumors [19],
colorectal cancer [20], renal cell carcinoma [21] and sar-
comas [6]. However, there has been a study reporting that
there was no prognostic impact of VM in pT3 and pT4
cutaneous melanoma [22]. To our knowledge, there have
been no reports on whether the presence of VM channels
would have an impact on the outcome of glioma patients.
In this study, our ﬁndings are consistent with the above-
mentioned results, that patients with VM positive tumors
have a shorter survival time than those without VM.
However, whether the poor prognosis of patients with VM
was due to a high pathological grade requires further
exploration. Patients in our study consisted of 60 cases of
high-grade gliomas. The Kaplan–Meier survival curve also
showed a signiﬁcant difference for survival times between
VM-positive and VM-negative groups (P = 0.008). How-
ever, when we analyzed the glioblastoma (only 21 cases)
group independently, there was no signiﬁcant difference of
survival time between VM-positive and VM-negative
groups (P = 0.493). This is not surprising, since we have
revealed that, although there was no signiﬁcant correlation
between MVD and survival time of the patients
(P = 0.110), the MVD were much higher in VM-negative
than in VM-positive high-grade gliomas (P = 0.039).
Thus, VM could be a complementation to ensure blood
supply, especially in regions of the gliomas with lower
MVD. Therefore, the phenomenon of patients with VM
positive gliomas having poorer prognosis may not, or at
least not only, be due to histological grade of the tumor.
Survival of patients with malignant astrocytomas has been
associated with several clinicopathological variables
including age, KPS of the patients, tumor grade, the extent
of surgical resection for tumors and postoperative radio-
therapy. Vasculogenic mimicry along with MVD could
also be deﬁned as one of the predictors for poor outcome of
the glioma patient.
The growth of tumor depends on angiogenesis and
microvascular adaptation. It has been well established that
the degree of vascularity correlates with increasing
malignancy [23] in gliomas. Zhang et al. [24] has proposed
a three-stage phenomenon among VM channels, mosaic
Table 3 Correlation of VM with MVD in high-grade gliomas
VM positive VM negative ZP value
MVD
(mean ± SD)
21.67 ± 20.05 45.17 ± 38.96 -2.064 0.039
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wherein all three patterns participate in tumor blood sup-
ply. Vasculogenesis/angiogenesis is the most recognized
cellular process that is activated in tumors to fulﬁll this
need. When tumors grow too rapidly, the current vascular
structure would not be able to provide sufﬁcient nutrients
and oxygen. Since not all high-grade gliomas possess a
high microvessel density, we can speculate that other fac-
tors may modulate the blood supply in these tumors. Tumor
cells may utilize their tremendous plasticity [25–28]t o
form vascular structures to mimic blood vessels [26] under
hypoxic conditions. In other words, when the level of MVD
would not be high enough to provide blood to tumors, VM
will develop, otherwise tumor necrosis could present. First,
while we found that the average level of MVD was higher
in high-grade gliomas than in low-grade gliomas, not all
the high-grade gliomas had a high level of MVD. Second,
although it has been reported [29, 30] that the level of
microvessels per microscopic ﬁeld has prognostic signiﬁ-
cance in astrocytomas, some researchers observed that the
level of MVD did not correlate with survival in paediatric
astrocytomas by univariate analysis [31]. We have also not
observed a signiﬁcant relationship between MVD and
prognosis of the glioma patients in this study. Thus, it is
possible that tumor angiogenesis requires the consideration
of other types of blood supply. Third, we have identiﬁed
two clear subgroups of patients based on VM channels in
the glioma specimen to analyze the relationship between
VM and MVD. Our data showed that MVD was compa-
rably less in VM-positive tumors than in VM-negative
tumors in high-grade gliomas. In all, we believe that the
existence of VM might provide a complementation to
ensure tumor blood supply, and may serve as another
mechanism to obtain nutrients for survival, especially in
less MVD regions of the gliomas.
Recently, Wang et al. [32] reported that the stem-cell-
like CD133(?) fraction from glioblastoma included a sub-
set of vascular endothelial-cadherin (CD144)-expressing
cells. They suggest that a subpopulation of the CD133(?)
cells were multipotent and capable of differentiation along
tumor and endothelial lineages. Though the detailed
molecular mechanisms for VM are not fully understood,
glioma stem cells (GSCs) might play a key role since GSCs
have been shown to be involved in tumor tissue remodeling
[28]. There has been evidence strongly suggesting that
GSCs are capable of forming blood vessels as well as
‘tubular vasculogenic mimicry’ de novo [27]. There is also
evidence of a physiological connection between the endo-
thelial-lined vasculature and the VM channel [28]. In other
words, VM is deﬁned by the unique ability of aggressive
tumor cells to express an endothelial cell phenotype.
In conclusion, the presence of VM is associated with
higher grade in gliomas, and may correlate with the
aggressive and invasive nature of gliomas. The existence of
VM may provide a complementation to ensure blood
supply, especially in less vascularized regions of the tumor.
Our data suggest that gliomas with VM-positive networks
may identify patients with poorer prognosis.
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